GlaxoSmithKline Pharmaceuticals share news, announcements and annual reports
NSE: GLAXOBSE: 500660Pharmaceuticals & BiotechnologyMid Cap
GlaxoSmithKline Pharmaceuticals Limited · Formerly Glaxo (India) · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Jan 1969 on BSE, Dec 2000 on NSE
Last close ₹2,494.30down ₹20.80 (0.83%)BSE ₹2,483.55
Share price at the NSE close on 30 Oct 2026. Previous close ₹2,515.10.
30 Oct: open ₹2,527.60, high ₹2,528.90, low ₹2,479.30
52-week range of traded prices to 30 Oct 2026
₹2,088.10Low, 12 Jun 2026₹3,120.70High, 28 Aug 2026
- Next results date: the board meets on 3 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹42,255 Cr221st largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 39.56
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 18.64
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 2.29%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 50.6%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 56.3%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.00
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 56,34965.0% delivered
GlaxoSmithKline Pharmaceuticals board and management
51 filed, newest first. Page 1 of 2.
Aug 2026
3 Aug · Management
May 2026
29 May · Management
29 May · Management
Apr 2026
21 Apr · Management
Mar 2026
16 Mar · Management
Oct 2025
29 Oct · Management
Jul 2025
9 Jul · Management
Jun 2025
2 Jun · Management
May 2025
13 May · Management
13 May · Management
2 May · Management
Apr 2025
4 Apr · Management
Mar 2025
26 Mar · Management
Feb 2025
Jan 2025
6 Jan · Management
6 Jan · Management
Dec 2024
30 Dec · Management
Jul 2024
5 Jul · Management
Feb 2024
28 Feb · Management
Dec 2023
29 Dec · Management
6 Dec · Management
Oct 2023
31 Oct · Management
Jul 2022
Jun 2022
May 2022
Feb 2022
7 Feb · Management
Nov 2021
25 Nov · Management
Jan 2021
7 Jan · Management
Oct 2020
28 Oct · Management
May 2020
18 May · Management
Mar 2020
3 Mar · Management
Feb 2019
4 Feb · Management
Jul 2018
24 Jul · Management
Mar 2018
Oct 2017
Apr 2017
Feb 2017
May 2016
Oct 2015
31 Oct · Management
Pursuant to Clause 30 of the Listing Agreement :1. Mr. P V Nayak, Non-Executive & Independent Director has ceased to be a Director of the Company from close of the business hours on 31st October 2015.2. Mr. V Thyagarajan, Non-Executive Director has ceased to be a Director of the Company from close of the business hours on 31st October 2015.
May 2015
Nov 2014
Feb 2013
19 Feb · Management
At the Meeting of the Board of Directors of the Company held on February 19, 2013, Ms. Anjali P. Bansal has been appointed as Non-Executive Independent Director with effect from February 19, 2013 in the casual vacancy caused due to resignation of Mr. V. Narayanan.
Nov 2011
8 Nov · Management
Board of Directors at its Meeting held on November 04, 2011, have appointed Mr. A.N. Roy as Additional Non-Executive Independent Director with effect from November 04, 2011.
Aug 2011
12 Aug · Management
Following changes in the Directorate with effect from August 01, 2011: (1) Mr. Raju Krishnaswamy has been appointed as an Executive Director- Technical. (2) Mr. Ashoke Banerjee has been appointed as Alternate Director to Mr. Simon Harford.
Nov 2010
2 Nov · Management
Boards of Directors at its Meeting held on October 28, 2010 have appointed Mr Simon Hardford as Non-retiring, Non-Executive Director and Mr. P V Bhide as Non-Executive Independent Director, both with effect from October 28, 2010.
May 2010
5 May · Management
As on the Board Meeting held on April 27, 2010, Mr. A . M. Nimbalkar has resigned as a Director of the Company with immediate effect.
Jul 2009
29 Jul · Management
Following changes in the Directorate with effect from July 27, 2009: 1) Mr. D. Sundaram has been appointed as an Independent Non-Executive Director in the casual vacancy caused by the resignation of Dr. Mark Reilly. 2) Mr. Ajit Nimbalkar has been appointed as an Additional Independent Non-Executive Director. 3) Mr. Peter Bains has resigned as a Director of the Company.